Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications
Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease
Dr. Hollander joins Ora after 10 years as industry leader at Allergan.
Meet Ora’s New Chief Medical Officer at ARVO
Ora, ophthalmic leader, deepens European foothold as part of Global expansion
Come visit Ora at booth #2131 or set up a meeting with us to learn about how we can help bring your product from concept to approval.
In this installment, we review another innovative project, exploring the progression of a product’s development, starting with the initial germination of the idea based on clinical observations.